Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,387 | 241 | 1,118 |
| Samples | 308 | 73 | 229 |
| Peptides | 268 | 54 | 220 |
Function
CDC25B · Cell division cycle 25B
CDC25B is a member of the CDC25 family of phosphatases. CDC25B activates the cyclin dependent kinase CDC2 by removing two phosphate groups and it is required for entry into mitosis. CDC25B shuttles between the nucleus and the cytoplasm due to nuclear localization and nuclear export signals. The protein is nuclear in the M and G1 phases of the cell cycle and moves to the cytoplasm during S and G2. CDC25B has oncogenic properties, although its role in tumor formation has not been determined. Multiple transcript variants for this gene exist. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 241 amino-acid changes on canonical ENST00000245960 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CDC25B · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CDC25B – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Endometrial Carcinoma | 3/42 7% | 9/612 1% |
| Colorectal Carcinoma | 5/143 4% | 51/3239 2% |
| Gastric Carcinoma | 5/74 7% | 21/1809 1% |
| Melanoma | 3/210 1% | 26/1899 1% |
| Mesothelioma | 1/62 2% | 2/165 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Cervical Carcinoma | 2/35 6% | 2/422 0% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Neuroendocrine Tumour | 6/154 4% | 0/577 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Hodgkins Lymphoma | 1/16 6% | 0/122 0% |
| Ovarian Carcinoma | 5/109 5% | 3/998 0% |
| Head and Neck Carcinoma | 2/85 2% | 10/1574 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 6/810 1% |
| Non-Small Cell Lung Carcinoma | 4/304 1% | 7/1390 0% |
| Ewings Sarcoma | 0/63 0% | 2/262 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 14/2550 1% |
| B-Cell Non-Hodgkins Lymphoma | 5/88 6% | 10/2534 0% |
| Plasma Cell Myeloma | 1/44 2% | 1/305 0% |
| Non-Cancerous | 0/104 0% | 5/830 1% |
| Hepatocellular Carcinoma | 1/46 2% | 10/2210 0% |
| Bladder Carcinoma | 3/58 5% | 2/956 0% |
| Breast Carcinoma | 7/144 5% | 9/3264 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Burkitts Lymphoma | 0/32 0% | 1/196 1% |
| Pancreatic Carcinoma | 1/89 1% | 6/1611 0% |
| Other Sarcomas | 2/69 3% | 1/699 0% |
Mutation Distribution
Where CDC25B is mutated · all tissues, split by cell line vs tissue
How many mutations in CDC25B were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,387 mutations in CDC25B
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|